

Blood and Infection

CAR-T

Chimeric Antigen Receptor T Cell (CAR T) Therapy

2207

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
CART01	Proportion of patients who complete treatment and are alive 28 days after infusion	Of those in the denominator, the number of patients who are alive 28 days after infusion	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
CART02	Proportion of patients who complete treatment and are alive 1 year after first infusion	Of those in the denominator, the number of patients who are alive 1 year after first infusion	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-21 - Mar-22
CART03	Proportion of patients who complete treatment and are alive 2 years after first infusion	Of those in the denominator, the number of patients who are alive 2 years after first infusion	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-20 - Mar-21
CART04a	Total number of patients with grade 3 or 4 CRS (Cytokine-release syndrome)	Total number of patients with grade 3 or 4 CRS (Cytokine-release syndrome)		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
CART04b	Total number of Incidences of CRS (Cytokine-release syndrome) at grade 2 and above requiring level 3 critical care or PICU	Total number of Incidences of CRS at grade 2 and above requiring level 3 critical care or PICU		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
CART05a	Total number of patients with grade 3 or 4 ICANS (Immune effector cell-associated neurotoxicity syndrome)	Total number of patients with grade 3 or 4 ICANS (Immune effector cell-associated neurotoxicity syndrome)		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
CART05b	Total number of Incidences of ICANS (Immune effector cell-associated neurotoxicity syndrome) requiring level 3 critical care or PICU	Total number of Incidences of ICANS (Immune effector cell-associated neurotoxicity syndrome) requiring level 3 critical care or PICU		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
CART07	Average duration of admission for patients where an incidence of CRS (Cytokine-release syndrome) at grade 2 and above has occurred	Length of stay (in days) of all patients following admitted	The total number of patients admitted where an incidence of CRS at grade 2 or above has occurred in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
CART08	Average duration of admission for patients where an incidence of ICANS (Immune effector cell-associated neurotoxicity syndrome) has occurred	Length of stay (in days) of all patients following admitted	The total number of patients admitted where an incidence of ICANS (Immune effector cell-associated neurotoxicity syndrome) has occurred in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
CART09	Average duration of admission for patients where an incidence of CRES (cell-related encephalopathy syndrome) at grade 2 and above has occurred	Length of stay (in days) of all patients following admitted	The total number of patients admitted where an incidence of CRES at grade 2 or above has occurred in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
CART10a	3 month mortality rate - due to treatment	Of those in the denominator, the number of patients who die within 3 months of completing treatment due to treatment	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
CART10b	3 month mortality rate - due to original disease	Of those in the denominator, the number of patients who die within 3 months of completing treatment due to original disease	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
CART11	Average length of stay of patients following treatment	Length of stay (in days) of all patients following completion of treatment	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23

Blood and Infection

CAR-T

Chimeric Antigen Receptor T Cell (CAR T) Therapy

2207

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
CART12	Average time from referral to clinical review	Length of time (in days) from referral being received to clinical review taking place	The total number of patients having a clinical review in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
CART13	Average time from first clinic appointment to apheresis date	Length of time (in days) from first clinic appointment to apheresis date	The total number of patients with date given for apheresis in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
CART14	Proportion of patients with long term cytopaenias lasting longer than 6 months	Of those in the denominator, the number of patients with long term cytopaenias lasting longer than 6 months	The total number of patients receiving treatment in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-21 - Mar-22
CART15	Proportion of patients requiring IVIG (Intravenous immunoglobulin) replacement	Of those in the denominator, the number of patients requiring IVIG (Intravenous immunoglobulin) replacement	The total number of patients receiving treatment in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23